Business Wire

ECCMID 2023: Shionogi Announces Real-World Evidence Demonstrating the Efficacy of Fetcroja® (cefiderocol) Against Some of the Most Difficult-to-Treat Gram-Negative Bacterial Pathogens

17.4.2023 07:01:00 EEST | Business Wire | Press release

Share

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announces key data for Fetcroja® (cefiderocol), an innovative siderophore cephalosporin, to be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), April 15-18, 2023, including new real-world evidence demonstrating its efficacy against some of the most difficult-to-treat Gram-negative bacterial infections.

In Europe, cefiderocol is commercially available under the brand name Fetcroja® for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.1 In the US, cefiderocol is available under the brand name Fetroja® and is indicated in patients 18 years of age or older for the treatment of hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia (HABP/VABP) and complicated urinary tract infections (cUTIs) caused by certain susceptible Gram-negative microorganisms.2

Interim results are emerging from PROVE (Retrospective Cefiderocol Chart Review), an ongoing international, retrospective study of the real-world use of cefiderocol for Gram-negative infections across EU and US sites.3,4 The study includes 194 patients with Pseudomonas aeruginosa infections treated with cefiderocol (123 from the US and 71 from the EU). These were generally seriously ill patients, many requiring mechanical ventilation and/or vasopressor support. The interim results show that cefiderocol achieved clinical cure in 65% of these patients, and 81% of patients were alive within 30 days of starting cefiderocol treatment. The patients principally had respiratory tract and bloodstream infections. Cefiderocol was initiated for a documented pathogen in the majority of cases (77%) and as monotherapy in 57% of patients.

Also in the study were 98 patients with Acinetobacter baumannii infections (71 from US and 27 from the EU). The patients had respiratory infection and bacteraemia as the most common infections. High levels of organ support were required in these patients, with 45% receiving mechanical ventilation and 30% requiring vasopressor support. Cefiderocol achieved clinical cure in 60% of patients, and 76% of patients were alive within 30-days of starting treatment. Cefiderocol was targeted as first treatment or as salvage therapy in 93% of patients, and as monotherapy in 41% of patients.

“These interim results from PROVE build on a growing body of real-world evidence across Europe and the US demonstrating the efficacy of cefiderocol in treating patients with life-threatening infections, such as Acinetobacter baumannii and Pseudomonas aeruginosa, the majority of whom are very sick with multiple comorbidities,” commented Prof. Dr. Dominic Wichmann, Consultant in department of Intensive Care Medicine, University of Hamburg-Eppendorf. “These are pathogens that fall into the World Health Organization’s critical priority list, for which effective treatments are urgently needed.”

Antimicrobial resistance (AMR)
Antimicrobial resistance (AMR) is a major health burden which urgently needs to be addressed. Globally, in 2019, there were 1.27 million deaths attributable to bacterial AMR.5 Infections caused by carbapenem-resistant Gram-negative bacteria are often associated with a high mortality rate.6 If no action is taken, antimicrobial resistance is predicted to kill 10 million people every year by 2050, at a cumulative cost to global economic output of 100 trillion USD.7

About FETCROJA® (Cefiderocol)
Cefiderocol is a siderophore cephalosporin antibiotic with an innovative mechanism for penetrating the outer cell membrane of Gram-negative pathogens by acting as a siderophore. In addition to entering cells by passive diffusion through porin channels, cefiderocol binds to ferric iron and is actively transported into bacterial cells through the outer membrane via the bacterial iron transporters, which function to incorporate this essential nutrient for bacteria.8 These mechanisms allow cefiderocol to achieve higher concentrations in the periplasmic space where it can bind to penicillin-binding proteins and inhibit cell wall synthesis in the bacterial cells.9 Cefiderocol has also demonstrated in vitro activity against certain bacteria that contain very problematic resistant enzymes such as ESBLs, AmpC, serine- and metallo-carbapenemases.10,11 Data from multinational surveillance studies for cefiderocol demonstrated potent in vitro activity against a wide spectrum of Gram-negative pathogens including carbapenem-resistant A. baumannii, P. aeruginosa, Enterobacterales, and S. maltophilia.12 The clinical significance of the in vitro data is unknown. Cefiderocol has no clinically relevant activity against Gram-positive or anaerobic bacteria.

FETCROJA® (Cefiderocol) INDICATION
In Europe, cefiderocol is commercially available under the brand name Fetcroja® for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.

Shionogi’s commitment to fighting antimicrobial resistance
Shionogi has a strong heritage in the field of anti-infectives and has been developing antimicrobial therapies for more than 60 years. Shionogi is proud to be one of the few large pharmaceutical companies that continues to focus on research and development in anti-infectives. The company invests the highest proportion of its pharmaceutical revenues in relevant anti-infectives R&D compared to other large pharmaceutical companies.13

For more information, please refer to: https://www.shionogi.com/global/en/sustainability/amr.html

About Shionogi
Shionogi & Co., Ltd. is a 145-year-old global, research-driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. Shionogi’s research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders.

For more information on Shionogi & Co., Ltd., please visit https://www.shionogi.com/global/en/

Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

© 2022 Shionogi Europe. All Rights Reserved.

References

1 FETCROJA SMPC. Available at: https://www.ema.europa.eu/en/documents/product-information/fetcroja-epar-product-information_en.pdf
Last accessed April 2023
2 Fetroja FDA prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209445s002lbl.pdf
Last accessed April 2023
3 Larcher R, et al. Real-world use of cefiderocol in the EU and US for Pseudomonas aeruginosa: interim data from the PROVE study. ECCMID abstract P2274
4 Timsit JF, et al. Real-world use of cefiderocol in the EU and US for Acinetobacter baumannii: interim data from the PROVE study. ECCMID abstract P2272
5 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022; 399: 629–55
6 Perez F, et al. ‘Carbapenem-Resistant Enterobacteriaceae: A Menace to our Most Vulnerable Patients’. Cleve Clin J Med. Apr 2013; 80(4): 225–33
7 O’Neill. The Review on antimicrobial resistance. 2016. Available at: https://amrreview.org/sites/default/files/160518_Final%20paper_with%20cover.pdf
Last accessed March 2023
8 Ito A, Nishikawa T., Masumoto S, et al. Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60(12):7396-7401
9 Tillotson GS. Trojan Horse Antibiotics—A Novel Way to Circumvent Gram-Negative Bacterial Resistance? Infectious Diseases: Research and Treatment. 2016;9:45-52 doi:10.4137/IDRT.S3156
10 K Kazmierczak et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). ). International Journal of Antimicrobial Agents, 2019; 53(2) 177-184
11 A Ito et al. In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2018, 62:e01454-17.
12 M Hackel, M Tsuji, Y Yamano, et al. In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, Against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem Non-Susceptible Isolates: The SIDERO-WT-2014 Study. Antimicrobial Agents Chemotherapy. 2017;61(9)
13 Antimicrobial Resistance Benchmark 2021. https://accesstomedicinefoundation.org/medialibrary/resources/61ee760d03810_Antimicrobial%20Resistance%20Benchmark%20report%202021.pdf
Last accessed April 2023

NP-EU-FDC-0414
April 2023

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Shionogi B.V.
Jo Taylor
Executive Director, Corporate and Government Affairs
jo.taylor@shionogi.eu

Havas SO Media Contact
Nicola Lilley
Associate Director
+44 (0)20 3196 9912
Nicola.lilley@havasso.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

UPS Announces Agreement to Acquire Smartways Logistics17.11.2026 23:00:00 EET | Press release

UPS (NYSE: UPS) today announced it has entered into an agreement to acquire Smartways Logistics (Smartways), a healthcare logistics provider serving Australia and New Zealand. Once completed, the acquisition will enhance UPS Healthcare’s time-critical transportation capabilities in the region. Smartways enables healthcare customers to move critical shipments quickly and reliably, with specialized services for life sciences, medical devices, clinical trials and radiopharmaceuticals. The acquisition will build on UPS Healthcare’s ability to deliver for customers with urgent and complex logistics needs, while expanding the services available in Australia, New Zealand and the Asia Pacific region. “As healthcare becomes increasingly complex, logistics plays an even more critical role. It takes specialized capabilities and precision at every step to help vital healthcare products reach patients safely, reliably and when they’re needed,” said Wilfredo Ramos, UPS EVP and Chief International, H

Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 21:10:00 EET | Press release

Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit

Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 20:00:00 EET | Press release

Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide

TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 19:04:00 EET | Press release

TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and strategic planning across therapeutics and diagnostics. Recently, he served as Chief Financial Officer of Bluebird Bio (

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye